Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Ítems similars

• Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
  per: van Rhee, Frits, et al.
  Publicat: (2010)
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
  per: Nair, Bijay, et al.
  Publicat: (2010)
• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  per: Waheed, Sarah, et al.
  Publicat: (2010)
• Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols
  per: Hoering, Antje, et al.
  Publicat: (2009)
• Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms
  per: Barlogie, Bart, et al.
  Publicat: (2010)